MINI FUTURE OPTIONSSCHEIN CALL - ELI LILLY & CO | Market Closed - Bid/Ask 19:04:51 20/06/2024 BST | ||
| 53.4 EUR | -1.87% |
|
| Current month | +16.48% | ||
| 1 month | +27.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 53.4 | -1.87% |
| 19/06/24 | 54.42 | +0.78% |
| 18/06/24 | 54 | +0.26% |
| 17/06/24 | 53.86 | +1.16% |
| 14/06/24 | 53.24 | +0.21% |
Real-time Boerse Frankfurt Warrants
Last update June 20, 2024 at 07:04 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | DZ BANK |
| WKN | DDZ7DX |
| ISIN | DE000DDZ7DX2 |
| Date issued | 07/03/2023 |
| Strike | 309.9 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.72 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 55.38 € |
|---|---|
| Lowest since issue | 2.65 € |
| Spread | 0.01 € |
| Spread % | 0.02% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
- Stock Market
- Certificates
- Certificat
